MedTrace Logo

Amisulpride Treatment for BPSD in AD Patients

NCT04341467 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2022-11-16

No results posted yet for this study

Summary

Currently, olanzapine is the most widely used and studied drug for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease, but there are significant side effects. Amisulpride is a new antipsychotic that not only controls mental symptoms but also improves cognitive function. Therefore, the aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and Olanzapine for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type.

Conditions

  • BPSD
  • Amisulpride
  • Olanzapine
  • Dementia of the Alzheimer Type

Interventions

DRUG

Amisulpride

The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.

DRUG

Olanzapine

The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.

Sponsors & Collaborators

  • Tianjin Anding Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2023-12-01
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341467 on ClinicalTrials.gov